Navigation Links
Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
Date:4/4/2012

CHICAGO, IL (April 4, 2012)When combined with other treatments, the drug cetuximabwhich works by slowing or stopping the growth of cancer cellshas been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patientsspecifically those who carry a mutated form of a gene called KRASdo not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175. The researchers from Fox Chase will present their findings at the AACR Annual Meeting 2012 on Wednesday, April 4.

In mice that had KRAS mutated colorectal cancer, researchers found that ARI-4175 not only blocked tumor growth when used alone, but also when used in combination with cetuximab. They hypothesize that the new drug may work by enlisting "natural killer" cells of the body's own immune system to reject the tumor.

"We've discovered that ARI-4175 appears to increase the level of natural killer cells that could play a role in rejecting the tumor," Hossein Borghaei, D.O., director of thoracic medical oncology at Fox Chase and lead author on the study says. He notes that this actionrallying the body's own immunologic defensesmay explain why ARI-4175 effectively stops the growth of tumors. "My theory is that this particular drug turns on the host's anticancer immune response, while cetuximab serves to help direct it toward the cancer."

Borghaei, along William W. Bachovchin, Ph.D., professor of biochemistry at Tufts Sackler School of Graduate Biomedical Sciences (also co-author on the study) and colleagues, tested ARI-4175 in colorectal cancer cell lines and in mice with two types of cetuximab-resistant colorectal tumors. Neither cetuximab nor ARI-4175, separately or together, succeeded in killing the cells in lab dishes. In the mice, however, ARI-4175 blocked tumor growth, and was more successful at higher doses of the drug. The research shows an even stronger effect in mice that received ARI-4175 combined with cetuximab.

Cetuximab, which is FDA-approved for metastatic colorectal cancer and some head and neck cancers, works by blocking a crucial receptor on the surface of a cancer cellcausing the cell to die. In people carrying the mutated form of the KRAS gene, cetuximab is not effective, but ARI-4175 may open up a detour around that impasse.

Borghaei notes that a cancer treatment like the immune stimulator ARI-4175, which uses the body's own defenses, may be more effective than drugs targeting tumor oncogenes that are susceptible to mutations that lead to resistance. "Tumors often develop resistance to targeted therapies," he says, "but it's more difficult to find resistance to a patient's own immune system. Bringing in the activity of the immune system might be the most effective way to fight some of these cancers."

"Our immune system can actually be a very useful partner in the fight against cancer," he says.

The researchers say their results suggest ARI-4175 warrants further testing in clinical trials. Although the researchers investigated colorectal cancer, their findings may also point to new approaches to treating other types of cancer. "If we can show that the drug overcomes resistance to cetuximab, it can be used against head and neck cancers as well," says Borghaei.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... , ... When faced with having to use a toilet away from home ... body, and contamination of children when they use public toilets. This inspired her to ... people face. , The patent-pending SANI-POCKET enables a person to use a public toilet ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... from offices in Pasco and Richland, is initiating a charity drive to support ... resulting from a recent automobile collision. , On October 29th of this ...
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman Company ... outserts. As a means of expanding capabilities Flottman has added a G&K ... individually code professional inserts (PIs) and patient package inserts (PPIs) that will marry ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund announced ... is recommending the film Whispering Spirits and its discussion guide for use ... an education tool in the war against teen drug abuse. NCADD is the ...
(Date:12/9/2016)... ... 2016 , ... An inventor from Cana, Va., wanted to fulfill the need ... park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. ... set up in a matter of minutes, or even seconds. The SAFETY STRAP FOR ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... HARRISBURG, Pa. , Dec. 9, 2016 ... today announced temporary regulations for medical marijuana dispensaries under ... The Pennsylvania Bulletin , and are now available ... what is needed in the plan for operation; process ... the dispensary; as well as where the dispensary facilities ...
(Date:12/8/2016)... 2016 Australia Glaucoma Surgery Devices Market ... report, "Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices market. The report provides value, ... and average prices (USD) within market segement - ... company shares and distribution shares data for each ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
Breaking Medicine Technology: